BioRationality: Bringing the FDA and the USP Together to Revolutionize Biosimilars
February 5th 2024
By Sarfaraz K. Niazi, PhD
ArticleIn his latest column, Sarfaraz K. Niazi, PhD, highlights challenges in biosimilar development, emphasizing the crucial role of US Pharmacopeia (USP) and advocating for collaboration and standardized guidelines to expedite cost-effective development without compromising safety or efficacy.